<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136352">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02134080</url>
  </required_header>
  <id_info>
    <org_study_id>1403013669</org_study_id>
    <nct_id>NCT02134080</nct_id>
  </id_info>
  <brief_title>FAAH Inhibitor Trial for Adults With Tourette Syndrome</brief_title>
  <official_title>FAAH Inhibitor Trial for Adults With Tourette Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tourette Syndrome Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to examine the safety, tolerability and feasibility in the use
      of a FAAH inhibitor for the treatment of adults with Tourette syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in Tic Severity</measure>
    <time_frame>Evaluated each time subject seen over approximately 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Yale Global Tic Severity Scale (Total Tic Score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Premonitory Urges</measure>
    <time_frame>Evaluated each time subject seen over approximately 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Premonitory Urge for Tics Scale (PUTS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Obsessive Compulsive Disorder (OCD) Severity</measure>
    <time_frame>Evaluated every two weeks over the course of approximately 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Report of Tic Severity</measure>
    <time_frame>Evaluated each time subject seen over approximately 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tourette Syndrome Symptom List (TSSL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Video-Tape Ratings of Tic Severity</measure>
    <time_frame>Evaluated every two weeks over the course of approximately 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modified Rush Video Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADHD Severity</measure>
    <time_frame>Evaluated every two weeks over the course of approximately 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Connors Adult Attention Deficit Hyperactivity Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity</measure>
    <time_frame>Evaluated every two weeks over the course of approximately 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hamilton Rating Scale for Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety Severity</measure>
    <time_frame>Evaluated every two weeks over the course of approximately 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hamilton Rating Scale for Anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall improvement</measure>
    <time_frame>Evaluated each time subject seen over approximately 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Global Improvement Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Evaluated each time subject seen over approximately 12 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse Events Rating Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Tourette Syndrome</condition>
  <arm_group>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PF-04457845 will be administered orally at 4mg daily for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sugar pill) will be administered orally at 4mg daily for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04457845</intervention_name>
    <description>PF-04457845 will be administered orally at 4mg daily for four weeks.</description>
    <arm_group_label>PF-04457845</arm_group_label>
    <other_name>fatty acid amide hydrolase (FAAH) inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally at 4mg daily for four weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult between 18-60 years of age

          -  Meet DSM IV criteria for the diagnosis of Tourette's syndrome

          -  Significant current tic symptoms: YGTSS total tic score greater than or equal to 22
             at baseline

          -  On stable psychiatric medication regimen for a minimum of 4 weeks prior to beginning
             the trial.

          -  Accepted method of birth control

        Exclusion Criteria:

          -  Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental
             disorder or intellectual disability (IQ&lt;70).

          -  Current use of medications that have significant effects on the cannabinoid or
             dopamine systems. Subjects will be specifically excluded for recent use (within last
             8 weeks) of antipsychotic medications, dopamine agonists or psychostimulants.

          -  Recent change (less than 4 weeks) in other medications that have potential effects on
             tic severity (such as alpha-2 agonists (guanfacine, clonidine or prazosin), SSRIs,
             clomipramine, naltrexone, lithium, anxiolytics, topiramate, baclofen etc.).
             Medication change is defined to include dose changes or medication discontinuation.

          -  Recent change in behavioral treatment for Tourette syndrome or comorbid conditions
             (i.e. OCD) within the last 4 weeks or initiation of behavioral therapy for tics
             within the last 12 weeks.

          -  Positive pregnancy test or drug screening test

          -  History of cannabis dependence

          -  Significant Medical Comorbidity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H. Bloch, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jilian M. Mulqueen, BA</last_name>
    <phone>203-737-4809</phone>
    <email>jilian.mulqueen@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jilian M. Mulqueen, BA</last_name>
      <phone>203-737-4809</phone>
      <email>jilian.mulqueen@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Michael H. Bloch, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tourette Syndrome</keyword>
  <keyword>FAAH-Inhibitor</keyword>
  <keyword>Tics</keyword>
  <keyword>Tic Disorders</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
